Left Atrial Appendage Occlusion Patents: Leaders & White Space 2026
Left Atrial Appendage Occlusion Patents: Who Leads and Where Claims Are Still Open
40.1% concentration. The top 5 of 87 ranked assignees hold 169 of 421 records in scope — the field is led but not closed. Filings climbed from 14 in 2017 to a peak of 56 in 2024, including a +167% rise between 2021 and 2024. 2025 and 2026 figures are still incomplete because of publication lag and should not be read as a decline.
- 1BOSTON SCIENTIFIC SCIMED INC38
- 2JAVELIN MEDICAL38
- 3ST JUDE MEDICAL CARDILOGY DIV INC36
- 4BOSTON SCI MEDICAL DEVICE LTD34
- 5LAMINAR INC23
See the full left atrial appendage occlusion analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on LAAO patenting
How many companies hold patents in left atrial appendage occlusion?
The assignee ranking for this dataset lists 87 companies across 421 records in scope. The leading assignee holds 38 records, with the fifth-ranked company at 23 and the tenth at 15, showing a gradual taper rather than a small number of firms owning the whole space. That means new entrants can still find open claim territory, particularly outside the core mechanical occluder designs held by the leaders.
Is the left atrial appendage occlusion patent field growing or slowing down?
Filings grew substantially, rising from 21 in 2021 to 56 in 2024, a +167% increase over that span and the highest year on record. The 2025 and 2026 figures look lower only because patent publication typically lags filing by about 18 months, so recent applications have not all surfaced in the data yet. Treat the 2024 peak as the most reliable recent signal, not the apparent dip after it.
What technology areas are most heavily claimed in LAAO patents?
A61B, covering diagnosis and surgery, appears in 83.8% of the 421 records in scope, making it by far the densest claim territory. A61F implant and prosthesis claims (24.9%) and A61M body-fluid device claims (20.0%) form a second tier. Because a single record can carry multiple IPC classes, these percentages overlap and add to more than 100%, which is expected rather than an error.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Left Atrial Appendage Occlusion covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.